Novartis
KYMRIAH
Manufacturer:
Novartis
Name:
KYMRIAH
HCPCS Code Descriptor:
Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Category:
Q Code
HCPCS:
Q2042
NDC(s):
00078-0846-19, 00078-0958-19
Primary Type:
Oncology
Generic Status:
Single-Source
Route of Administration:
Intravenous
About:
KYMRIAH is an Oncology drug manufactured by Novartis and administered via the Intravenous route of administration. The Q Code: Q2042 is aligned to the drug KYMRIAH.